was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Patient Focused: We realize that every sample that comes through our laboratory has a patient behind it and it is our job to ensure that we handle each sample with care and provide results back to the patient and physician in a timely manner. PreludeDx exists to take care of the needs of our patients.
Quality First: We will put quality systems and processes first and foremost as we provide the highest quality results to our patients and physicians.
Driving Innovation: PreludeDx will strive to find new innovative tools and processes that assist patients and physicians for the better management of cancer.
DCISionRT is the only test capable of predicting an individual patient’s benefit from radiation therapy. Using DCISionRT provides you with 10-year Total and Invasive Recurrence Risk after breast conserving surgery as well as surgery with radiation therapy. No other test can do this.
For more information please visit www.preludedx.com
At Pfizer Oncology
, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of innovative cancer medicines and biosimilars across more than 20 indications, including breast, prostate, kidney, lung and hematology. We are striving to change the trajectory of cancer.
For more information please visit www.pfizer.com